Abstract: New soybean varieties designated ‘20311965’, ‘3520224’, ‘20273637’, ‘20273641’, ‘21237491’, ‘20272663’, ‘10021388457’, ‘10021387697’, ‘20273650’, ‘21237431’, ‘21237487’, ‘10021387142’, and ‘20272659’ are soybean varieties exhibiting stability and uniformity.

Abstract: New soybean varieties designated ‘10020720647’, ‘10020889109’, ‘10020889166’, ‘70020032728’, ‘70020032975’, ‘70020033154’, ‘20598563’, ‘21097024’, ‘10021387700’, ‘10021389471’, ‘10021384531’, ‘10021387127’, ‘10020865219’, ‘10021384221’, ‘21097118’, ‘10021389525’, and ‘10021384485’, are soybean varieties exhibiting stability and uniformity.

Abstract: The invention discloses a soybean plant, or a part of said plant comprising the transgenic event CIGBDt-Def1 or the transgenic event CIGBIs-Def5, as well as a method for the detection of those events in soybean samples. It also provides a seed from a soybean plant comprising said transgenic events, and products obtained from a plant, or from soybean seeds, comprising one of said events. In addition, the invention is related to a method for the production of soybean plants resistant to glyphosate, and to diseases caused by fungi or oomycetes, comprising the introduction of one of the mentioned transgenic events in the genome of said plants. The increase in the yield of a soybean crop in the field can be achieved with the transgenic events of the invention.

Abstract: This invention reveals the pharmaceutical composition that includes the surface antigen (HBsAg) of the hepatitis B virus (HBV) and the antigen of the nucleocapsid (or core, HBcAg) of the same virus. The HBcAg of this composition contains messenger ribonucleic acid (mRNA) at a proportion of over 45% of the total amount of ribonucleic acid (RNA) in this antigen. Because of the changes in the constitution of the antigens forming it, the composition of the invention is useful for the prevention or treatment of chronic hepatitis B. It also covers the use of this pharmaceutical composition in the production of a drug for immuno-prophylaxis or immunotherapy against HBV infection, and its use to increase the immune response against an additional antigen that is co-administered with the mixture of these antigens.

Abstract: The present invention relates to a method for identifying and selecting plants resistant to a fungal disease comprising the steps of; (a) extraction of nucleic acid from a plant; (b) analysis of extracted nucleic acid for the presence of markers associated with increased fungal resistance within a single chromosome interval; and (c) selection of the plants that have these markers. Furthermore, the invention also relates to a method for introgression into plants of fungal disease resistance alleles comprising the steps of; (a) crossing parents of plants identified by the first embodiment method with other parents that do not have this resistance; (b) select progenies possessing markers associated with increased resistance to fungal disease using the method as defined in the first achievement; and (c) backcross in one or more cycles the selected progenies with the recurrent genitor to develop new progenies.

Abstract: The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing the compounds.

Abstract: A new and distinct cultivar of Poinsettia plant named ‘LAZZPO1615’, characterized by its compact, upright “V”-shaped and uniformly mounding plant habit; moderately vigorous growth habit; freely branching habit and strong stems; dark green-colored leaves; full inflorescences with medium to large bright red-colored flower bracts; and excellent post-production longevity.

Abstract: A new and distinct cultivar of Poinsettia plant named ‘LAZZP01531’, characterized by its upright “V”- shaped and uniformly mounding plant habit; moderately vigorous to vigorous growth habit; freely branching habit and strong stems; dark green-colored leaves; full inflorescences with medium to large deep red-colored flower bracts; and excellent post-production longevity.

Abstract: The present invention is related to the use of the growth hormone releasing peptide-6 (GHRP-6) for the manufacture of a late cardioprotective and cardiac restoration medicament. Said late cardioprotective and cardiac restoration medicament comprises GHRP-6 and a pharmaceutically acceptable excipient or vehicle. It also provides a method for the treatment of a disease that involves a low cardiac output, wherein a therapeutically effective amount of a late cardioprotective and cardiac restoration medicament comprising GHRP-6 is administered to a subject in need. Said medicament allows treating in a late manner, even days later, the myocardium that suffered episodes of stunning, hibernation, ischemia and its consequences thereof.

Abstract: The invention relates to vesicles comprising Epidermal Growth Factor (EGF), a cationic surfactant and cholesterol or derivatives thereof. The invention also discloses a procedure for their preparation, based on compressed fluid technology (CFs). The vesicles of the invention are useful in the manufacture of drugs and cosmetics and in tissue engineering.

Abstract: This invention reveals the pharmaceutical composition that includes the surface antigen (HBsAg) of the hepatitis B virus (HBV) and the antigen of the nucleocapsid (or core, HBcAg) of the same virus. The HBcAg of this composition contains messenger ribonucleic acid (mRNA) at a proportion of over 45% of the total amount of ribonucleic acid (RNA) in this antigen. Because of the changes in the constitution of the antigens forming it, the composition of the invention is useful for the prevention or treatment of chronic hepatitis B. It also covers the use of this pharmaceutical composition in the production of a drug for immuno-prophylaxis or immunotherapy against HBV infection, and its use to increase the immune response against an additional antigen that is co-administered with the mixture of these antigens.

Abstract: The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing the compounds.

Abstract: The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing the compounds.

Abstract: The present invention is related to the use of the GHRP-6 and one structural analogue as molecular adjuvants for vaccines. Among other applications, these vaccines may be employed for preventing diseases caused by infectious agents, like viruses, bacteria and ectoparasites, that affect mammals, birds and aquatic organisms. The GHRP-6 and its analogue A233 are effectives as adjuvants when they are combine with a given antigen, since they enhance the specific immune response against it.

Abstract: The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing said compounds.

Abstract: The following invention discloses a method for the control of plant diseases wherein a composition comprising a compound having the structure represented by one of the formulas from I to V, is applied to the plants. It also discloses the use of said compounds, or their salts for the stimulation of the natural defense and the induction of resistance against plant diseases. Moreover, it comprises the use of said compounds of structure represented by one of the formulas from I to V for the preventive or curative treatment of said diseases. A composition for agriculture, comprising a compound having the structure represented by one of the formulas from I to V, is also part of the invention.

Abstract: A new and distinct cultivar of Osteospermum plant named ‘LAZOST1803’, characterized by its compact, uniform and mounding plant habit; moderately vigorous growth habit; freely and uniformly branching habit; freely and early flowering habit; large single-type inflorescences with white-colored ray florets with a reddish purple-colored central ring; and good garden performance.

Abstract: A new and distinct cultivar of Poinsettia plant named ‘LAZZPO1531’, characterized by its upright “V”-shaped and uniformly mounding plant habit; moderately vigorous to vigorous growth habit; freely branching habit and strong stems; dark green-colored leaves; full inflorescences with medium to large deep red-colored flower bracts; and excellent post-production longevity.

Abstract: A new and distinct cultivar of Osteospermum plant named ‘LAZOST1831’, characterized by its uniform and mounding plant habit; moderately vigorous growth habit; freely and uniformly branching habit; freely and early flowering habit; large single-type inflorescences with red purple and darker red purple bi-colored ray florets; and good garden performance.

Abstract: A new and distinct cultivar of Poinsettia plant named ‘LAZZPO1615’, characterized by its compact, upright “V”-shaped and uniformly mounding plant habit; moderately vigorous growth habit; freely branching habit and strong stems; dark green-colored leaves; full inflorescences with medium to large bright red-colored flower bracts; and excellent post-production longevity.